News - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
Most recent news, press releases and media releases on Clarity Pharmaceuticals| Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
Most recent news, press releases and media releases on Clarity Pharmaceuticals| Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
The post Clarity signs copper-67 Supply Agreement with Nusano appeared first on Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging.| Clarity Pharmaceuticals – Radiopharmaceutical Therapies and Imaging
The post Co-PSMA trial achieves primary endpoint appeared first on Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging.| Clarity Pharmaceuticals – Radiopharmaceutical Therapies and Imaging
The post Data on Clarity’s SAR-bisFAP to be presented at the World Molecular Imaging Conference 2025 appeared first on Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging.| Clarity Pharmaceuticals – Radiopharmaceutical Therapies and Imaging
The post Clarity confirms US-based manufacturing in response to newly announced tariff on pharmaceuticals appeared first on Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging.| Clarity Pharmaceuticals – Radiopharmaceutical Therapies and Imaging
The post Clarity successfully completes $203 million institutional placement appeared first on Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging.| Clarity Pharmaceuticals – Radiopharmaceutical Therapies and Imaging
The post Co-PSMA trial: Recruitment successfully completed appeared first on Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging.| Clarity Pharmaceuticals – Radiopharmaceutical Therapies and Imaging
The post Clarity enters a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx appeared first on Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging.| Clarity Pharmaceuticals – Radiopharmaceutical Therapies and Imaging
The post SABRE topline results: Cu-64 SAR-Bombesin is effective in detecting prostate cancer recurrence in patients with negative SOC imaging appeared first on Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging.| Clarity Pharmaceuticals – Radiopharmaceutical Therapies and Imaging
The post DISCO topline results: Cu-64 SARTATE is highly effective in detecting tumours in NET patients compared to SOC imaging. Phase III planning underway. appeared first on Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging.| Clarity Pharmaceuticals – Radiopharmaceutical Therapies and Imaging
[vc_row][vc_column][vc_column_text css=””]Sydney, Australia 29 May 2025[/vc_column_text][vc_column_text css=””]Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that it has imaged the first patient in its registrational Phase III 64Cu-SAR-bisPSMA diagnostic trial in participants with biochemi...| Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
Clarity is a clinical stage company developing products to address the growing need for the use of radiopharmaceuticals in oncology.| Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
Copper-based theranostic radiopharmaceutical with increased specificity and in-vivo stability, being developed for diagnosing and treating prostate cancer| Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
[vc_row][vc_column][vc_column_text]Sydney, Australia 15 February 2024 Highlights Initial data from Clarity’s diagnostic Phase 1/2 trial, COBRA, confirms 64Cu-SAR-bisPSMA is safe and highly effective in detecting prostate cancer (PC) lesions in patients with biochemical recurrence (BCR). Confirmed unique benefit of 64Cu-SAR-bisPSMA for next-day imaging in this patient population, with more lesions and more patients with a positive…| Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
